Skip to main content
Contact Us
Subscribe
E-Edition
36°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuneering Corp Cl A
(NQ:
IMRX
)
2.130
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuneering Corp Cl A
< Previous
1
2
3
4
5
Next >
What 7 Analyst Ratings Have To Say About Immuneering
April 19, 2023
Via
Benzinga
Immuneering Announces $30 Million Underwritten Offering
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Why Shares of Immuneering Jumped This Week
March 24, 2023
Immuneering is ready to share information regarding its lead therapy.
Via
The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
April 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 06, 2023
Via
Benzinga
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
April 05, 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 -
From
Immuneering Corporation
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
March 28, 2023
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
March 14, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
March 14, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Looking Into Immuneering's Return On Capital Employed
March 09, 2023
Via
Benzinga
Immuneering Earnings Preview
March 03, 2023
Via
Benzinga
Immuneering's Return On Capital Employed Insights
December 20, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 08, 2023
Via
Benzinga
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
March 05, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in March Investor Conferences
February 28, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 27, 2023
Management to host conference call on Monday, March 6 at 4:30 p.m. ET
From
Immuneering Corporation
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Immuneering To Present at Guggenheim 2023 Oncology Conference
January 31, 2023
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
November 28, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
November 10, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Announces Participation in November Investor Conferences
November 03, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Appoints Leah R. Neufeld as Chief People Officer
October 20, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 05, 2022
From
Immuneering Corporation
Via
GlobeNewswire
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
September 30, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.